论文部分内容阅读
生物工程技术近年来在中国被炒得很热,很多高技术公司纷纷涉足这一领域,一时间各类脑黄金、各种口服液的广告宣传铺天盖地而来,给国人造成一种印象:生物技术产业在中国正狂潮猛进。 然而,事实怎样呢?本期焦点文章的作者徐风同志道出了个中真相:“急速繁荣后的长久危机”——投资规模大、时间长、效益低。 生物工程技术作为21世纪前沿技术,在全球已成为最重要的朝阳工业,它在提高人类的生活质量、健康水平的同时,将产生高额的经济利润,已经成为不争的事实。正因为如此,这一领域的全球范围内的竞争也就异常激烈。 中国作为生物制品大国,在这场竞争中似乎并没有显示出它应有的优势,以至业内人士发出了充满危机的信号。
In recent years, bioengineering technology has been very hot in China. Many high-tech companies have set foot in this field. For a time, various types of brain gold and various oral liquid ads spread over the world, giving people the impression that biotechnology Industry is frenzied in China. However, what is the truth? Xu Feng, author of this issue’s focus article, tells the truth: “the long-term crisis after a rapid boom” - with a large investment scale, long period of time and low efficiency. As the cutting-edge technology in the 21st century, bioengineering technology has become the most important sunrise industry in the world. It has become an indisputable fact that it will generate high economic profits while improving the quality of life and health of human beings. Because of this, the global competition in this area is extremely fierce. As a big biological country, China does not seem to have demonstrated its advantages in this competition. As a result, the industry sent a signal of crisis.